Document 0724
 DOCN  M94A0724
 TI    In-field assay monitoring of anti-HIV-1/HIV-2 EIAs in Australian Blood
       Banks, 1992. Australian Red Cross Blood Transfusion Service
       Laboratories.
 DT    9412
 AU    Dax EM; Bendistinto M; Vandenbelt T; National HIV Reference Laboratory
       (NRL), Fairfield Hospital,; Victoria, Australia.
 SO    Annu Conf Australas Soc HIV Med. 1993 Oct 28-30;5:111 (poster no. 72).
       Unique Identifier : AIDSLINE ASHM5/94348931
 AB    OBJECTIVE: To examine the performance of 4 anti-HIV-1/HIV-2 enzyme
       immunoassays (EIAs) in Australian Blood Banks during use. EIAs included:
       Abbott Recombinant, Diagnostic Pasteur Genelavia MIXT, Genetic Systems
       EIA and Organon Teknika. METHODS: Anti-HIV-1/HIV-2 EIAs were monitored
       by collecting data from individual laboratories each month. The data
       included number of specimens tested, number of specimens found to be
       initially reactive, and repeatably reactive per week. Assay batch
       numbers were also recorded. Data were relayed to the NRL as part of the
       regular assay monitoring procedures used in the quality assurance
       program in Australia. Initial (IRR) and repeat reactor rates (RRR) were
       calculated for each assay and batch. Overall mean 'in-field'
       specificities (Sp.) were calculated as 100-RRR% and compared with
       evaluation specificities (Eval. Sp.) found during formal evaluation
       using 5000 fresh donations for each assay. RESULTS: The Genetic Systems
       EIA showed the least variation between batches (N = 4) while others
       demonstrated 3-4 fold variation in RRR. The Organon and Pasteur batches
       showed large variation between IRR and RRR, suggesting that these EIAs
       are prone to technical error. (see table below) CONCLUSION: Three of the
       HIV-1/HIV-2 EIAs demonstrated 'in-field' specificity within the
       evaluation specificity range. TABULAR DATA, SEE ABSTRACT VOLUME.
 DE    Australia  *Blood Banks  *Blood Transfusion  Human  HIV
       Infections/*PREVENTION & CONTROL/TRANSMISSION  HIV-1/*ISOLATION & PURIF
       HIV-2/*ISOLATION & PURIF  *Immunoenzyme Techniques  Mass Screening
       Quality Control  Red Cross  MEETING ABSTRACT

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).